# US 2026/0092095 A1 · Interleukin-2 for use in treating autism spectrum disorder

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0092095 A1
- Document ID: US20260092095A1
- Status: Published application
- Kind: A1
- Application number: 19/110,627
- Filed: 2022-09-12
- Published: 2026-04-02
- Earliest claimed: 2022-09-12
- Assignees: Inserm (Institut National De La Santé Et La Recherche MéDicale); Sorbonne Universite; Assistance Publique-Hopitaux de Paris
- Applicants: Inserm (Institut National De La Santé Et La Recherche MéDicale); Sorbonne Universite; Assistance Publique-HôPitaux De Paris
- Inventors: David Klaatzman; Pierre Ellul; Michelle Rosenzwajg; Richard Delorme; Gwladys Fourcade
- Web page: https://patentgrep.com/patent/US20260092095A1

## CPC

- A61K 38/2013: {IL-2}
- C07K 14/55: IL-2
- A61P 25/00: Drugs for disorders of the nervous system
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to the use of IL-2 in treating autism spectrum disorder (ASD) in a subject, as well as in preventing ASD in children, by administering the IL-2 to a child at risk of ASD or to a pregnant mother at risk of having a child with ASD.

## Claims

### Claim 1

Interleukin-2 (IL-2) for use in treating autism spectrum disorder (ASD) in a subject.

### Claim 2 (depends on 1)

The IL-2 for use according to claim 1, wherein the subject is a child who has been diagnosed with ASD, preferably wherein the child is between 1 and 8 years old.

### Claim 3

Interleukin-2 (IL-2) for use in preventing autism spectrum disorder (ASD) in a subject, wherein the IL-2 is administered to the subject who is an infant or a child, preferably wherein the infant or child is at risk of ASD.

### Claim 4

Interleukin-2 (IL-2) for use in preventing autism spectrum disorder (ASD) in an infant or a child, wherein the IL-2 is administered to a pregnant mother.

### Claim 5 (depends on 4)

The IL-2 for use according to claim 4, wherein the pregnant mother is at risk of having a child with ASD, optionally wherein the pregnant mother is with ASD herself, or is or has been affected with an infection during pregnancy, or is affected with an autoimmune disease or inflammatory disorder and/or optionally wherein the pregnant mother already had a child who developed ASD, or with anti-fetal brain antibodies.

### Claim 6 (depends on 4, 5)

The IL-2 for use according to claim 4 or 5, wherein the IL-2 is administered during the first trimester of pregnancy.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The IL-2 for use according to any of claims 1 to 6, wherein the IL-2 is administered at a maximum dose of 3.5 MIU/day or less, preferably 3 MIU/day or less, still preferably 2 MIU/day or less, still preferably at a dose of between 0.1 and 1.5 or 2 MUI/day.

### Claim 8 (depends on 1, 2, 3)

The IL-2 for use according to any of claims 1-3, wherein the IL-2 is administered to a child at a dose of between 0.1 and 1 MUI/day, or between 0.5 and 1 MIU/day.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The IL-2 for use according to any of claims 1 to 8, wherein the IL-2 is administered repeatedly, preferably in a first course that preferably consists of at least one daily administration during 1 to 7 days, followed by a maintenance course after at least 5 days, which maintenance course preferably comprises or consists of at least one administration once every week during 1 week to 3 months.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The IL-2 for use according to any of claims 1 to 9, wherein said IL-2 is human IL-2 or aldesleukin or an active analogue thereof, wherein said active analogue has at least 85% or 90% amino acid identity with human wild-type IL-2, and is capable of activating Tregs, still preferably wherein said analogue is preferably an IL2 mutein that comprises a substitution at position N88 of SEQ ID NO: 2, still preferably substitution N88R or N88D.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The IL-2 for use according to any of claims 1 to 10, wherein said IL-2 is conjugated to a PEG moiety, an Fc fragment, or any other moiety that improves the half-life of IL-2 or its diffusion in the central nervous system.

### Claim 12 (depends on 11)

The IL-2 for use according to claim 11, wherein said IL-2 is conjugated to a beta chain of the C4b-binding protein (C4BP ) or at least one fragment or functional variant thereof that is capable of forming a dimeric protein, preferably wherein the fragment of C4BP comprises, or consists of, amino acid residues 194 to 252 of C4BP or a longer fragment of C4BP that extends at the N-term up to at most amino acid 135.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The IL-2 for use according to any of claims 1 to 12, wherein said IL-2 is expressed in vivo after administration with a nucleic acid encoding said IL-2.

### Claim 14 (depends on 13)

The IL-2 for use according to claim 13, wherein the nucleic acid is carried by an RNA or a viral vector, preferably an adeno-virus associated virus (AAV).

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The IL-2 for use according to any of claims 1 to 14, wherein said IL-2 is administered by subcutaneous, intramuscular or intradermal route.
